HomeCompareHEWA vs ABBV

HEWA vs ABBV: Dividend Comparison 2026

HEWA yields 1666.67% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HEWA wins by $1839785666.15M in total portfolio value
10 years
HEWA
HEWA
● Live price
1666.67%
Share price
$0.12
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1839785666.26M
Annual income
$1,645,561,548,268,653.00
Full HEWA calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — HEWA vs ABBV

📍 HEWA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHEWAABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HEWA + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HEWA pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HEWA
Annual income on $10K today (after 15% tax)
$141,666.67/yr
After 10yr DRIP, annual income (after tax)
$1,398,727,316,028,355.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, HEWA beats the other by $1,398,727,316,006,488.20/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HEWA + ABBV for your $10,000?

HEWA: 50%ABBV: 50%
100% ABBV50/50100% HEWA
Portfolio after 10yr
$919892833.18M
Annual income
$822,780,774,147,189.40/yr
Blended yield
89.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HEWA
No analyst data
Altman Z
-0.9
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HEWA buys
0
ABBV buys
0
No recent congressional trades found for HEWA or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHEWAABBV
Forward yield1666.67%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$1839785666.26M$104.7K
Annual income after 10y$1,645,561,548,268,653.00$25,725.73
Total dividends collected$1825787439.21M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HEWA vs ABBV ($10,000, DRIP)

YearHEWA PortfolioHEWA Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$177,367$166,666.67$11,559$438.51+$165.8KHEWA
2$2,952,503$2,762,720.66$13,494$640.86+$2.94MHEWA
3$46,139,686$42,980,507.73$15,951$945.97+$46.12MHEWA
4$677,098,258$627,728,794.51$19,152$1,413.89+$677.08MHEWA
5$9,333,745,461$8,609,250,324.41$23,443$2,146.38+$9333.72MHEWA
6$120,900,966,251$110,913,858,608.07$29,391$3,321.96+$120900.94MHEWA
7$1,472,054,345,780$1,342,690,311,890.92$37,948$5,265.87+$1472054.31MHEWA
8$16,853,789,214,559$15,278,691,064,574.45$50,795$8,596.74+$16853789.16MHEWA
9$181,517,867,281,133$163,484,312,821,554.84$71,034$14,549.41+$181517867.21MHEWA
10$1,839,785,666,259,465$1,645,561,548,268,653.00$104,715$25,725.73+$1839785666.15MHEWA

HEWA vs ABBV: Complete Analysis 2026

HEWAStock

HealthWarehouse.com, Inc. operates an online and mail order pharmacy. The company markets a range of generic, brand name, and pet prescription medicines, as well as over-the-counter (OTC) medications and products. It sells its products in 50 states and the District of Columbia in the United States to focus on the out-of-pocket prescription drug market. The company sells prescription medications and OTC products to individual consumers over the Internet. HealthWarehouse.com, Inc. is headquartered in Florence, Kentucky.

Full HEWA Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this HEWA vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HEWA vs SCHDHEWA vs JEPIHEWA vs OHEWA vs KOHEWA vs MAINHEWA vs JNJHEWA vs MRKHEWA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.